Suppr超能文献

噬菌体疗法——挑战、机遇与未来前景

Phage Therapy-Challenges, Opportunities and Future Prospects.

作者信息

Zalewska-Piątek Beata

机构信息

Department of Molecular Biotechnology and Microbiology, Chemical Faculty, Gdańsk University of Technology, Narutowicza 11/12, 80-233 Gdańsk, Poland.

出版信息

Pharmaceuticals (Basel). 2023 Nov 22;16(12):1638. doi: 10.3390/ph16121638.

Abstract

The increasing drug resistance of bacteria to commonly used antibiotics creates the need to search for and develop alternative forms of treatment. Phage therapy fits this trend perfectly. Phages that selectively infect and kill bacteria are often the only life-saving therapeutic option. Full legalization of this treatment method could help solve the problem of multidrug-resistant infectious diseases on a global scale. The aim of this review is to present the prospects for the development of phage therapy, the ethical and legal aspects of this form of treatment given the current situation of such therapy, and the benefits of using phage products in persons for whom available therapeutic options have been exhausted or do not exist at all. In addition, the challenges faced by this form of therapy in the fight against bacterial infections are also described. More clinical studies are needed to expand knowledge about phages, their dosage, and a standardized delivery system. These activities are necessary to ensure that phage-based therapy does not take the form of an experiment but is a standard medical treatment. Bacterial viruses will probably not become a miracle cure-a panacea for infections-but they have a chance to find an important place in medicine.

摘要

细菌对常用抗生素的耐药性不断增加,这就需要寻找和开发替代治疗方法。噬菌体疗法完全符合这一趋势。选择性感染并杀死细菌的噬菌体往往是唯一能挽救生命的治疗选择。这种治疗方法的全面合法化有助于在全球范围内解决多重耐药性传染病问题。本综述的目的是介绍噬菌体疗法的发展前景、鉴于这种疗法的现状其在伦理和法律方面的情况,以及在现有治疗选择已经用尽或根本不存在的人群中使用噬菌体产品的益处。此外,还描述了这种疗法在对抗细菌感染方面面临的挑战。需要更多的临床研究来扩大对噬菌体、其剂量和标准化给药系统的了解。这些活动对于确保基于噬菌体的疗法不采取实验形式而是成为标准医学治疗是必要的。细菌病毒可能不会成为一种神奇的疗法——治疗感染的万灵药——但它们有机会在医学中占据重要地位。

相似文献

1
Phage Therapy-Challenges, Opportunities and Future Prospects.
Pharmaceuticals (Basel). 2023 Nov 22;16(12):1638. doi: 10.3390/ph16121638.
4
Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development.
Pharmaceuticals (Basel). 2021 Apr 5;14(4):331. doi: 10.3390/ph14040331.
5
Phage steering of antibiotic-resistance evolution in the bacterial pathogen, .
Evol Med Public Health. 2020 Jul 11;2020(1):148-157. doi: 10.1093/emph/eoaa026. eCollection 2020.
6
Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
J Antimicrob Chemother. 2014 Sep;69(9):2326-36. doi: 10.1093/jac/dku173. Epub 2014 May 28.
7
Phage and phage cocktails formulations.
Prog Mol Biol Transl Sci. 2023;200:159-169. doi: 10.1016/bs.pmbts.2023.04.007. Epub 2023 May 5.
8
Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment.
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1467. doi: 10.3390/ph16101467.
9
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.
World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173. doi: 10.4292/wjgpt.v8.i3.162.
10
The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria.
Pharmaceuticals (Basel). 2023 Sep 24;16(10):1347. doi: 10.3390/ph16101347.

引用本文的文献

2
Reconstructing the Antibiotic Pipeline: Natural Alternatives to Antibacterial Agents.
Biomolecules. 2025 Aug 18;15(8):1182. doi: 10.3390/biom15081182.
3
Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.
Microb Biotechnol. 2025 Aug;18(8):e70218. doi: 10.1111/1751-7915.70218.
7
Bacteriophage-based strategies for biocontrol and treatment of infectious diseases.
Comput Struct Biotechnol J. 2025 Jun 30;27:2924-2932. doi: 10.1016/j.csbj.2025.06.046. eCollection 2025.
8
Efficacy of phage therapy in controlling staphylococcal biofilms: a systematic review.
Eur J Med Res. 2025 Jul 9;30(1):605. doi: 10.1186/s40001-025-02781-3.
10
Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases.
Microorganisms. 2025 May 23;13(6):1188. doi: 10.3390/microorganisms13061188.

本文引用的文献

2
Current Clinical Landscape and Global Potential of Bacteriophage Therapy.
Viruses. 2023 Apr 21;15(4):1020. doi: 10.3390/v15041020.
4
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation.
Clin Microbiol Infect. 2023 Jun;29(6):702-709. doi: 10.1016/j.cmi.2023.01.021. Epub 2023 Feb 2.
5
Phage therapy: From biological mechanisms to future directions.
Cell. 2023 Jan 5;186(1):17-31. doi: 10.1016/j.cell.2022.11.017.
6
Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era.
Acta Pharm Sin B. 2022 Dec;12(12):4348-4364. doi: 10.1016/j.apsb.2022.05.007. Epub 2022 May 13.
7
Approaches for bacteriophage genome engineering.
Trends Biotechnol. 2023 May;41(5):669-685. doi: 10.1016/j.tibtech.2022.08.008. Epub 2022 Sep 15.
8
Corrigendum: Development of phage cocktails to treat catheter-associated urinary tract infection and associated biofilms.
Front Microbiol. 2022 Aug 9;13:953136. doi: 10.3389/fmicb.2022.953136. eCollection 2022.
9
CRISPR-Cas9 Based Bacteriophage Genome Editing.
Microbiol Spectr. 2022 Aug 31;10(4):e0082022. doi: 10.1128/spectrum.00820-22. Epub 2022 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验